Macroaggregated Albumin Particle Preparation via Automated pH and Temperature Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing macroaggregated albumin particles for radiopharmaceutical use are complex, time-consuming, and economically inefficient, leading to variations in particle size distribution and density, which affect the quality and reproducibility of radiolabeled products.
Innovation Solution
A robust, simple, and time-saving process for preparing macroaggregated albumin particles using an automated reactor with controlled pH, stirring speed, and heating/cooling rates, eliminating the need for ultrafiltration and size screening, and ensuring consistent particle size distribution and density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional processes are used to prepare macroaggregated albumin particles, then the formulation can be produced, but the process is complex, time-consuming, and economically inefficient
Solution Approach 1:
The invention removes unnecessary purification steps (ultrafiltration) and size screening operations from the conventional process. By directly aggregating albumin without these intermediate steps, the process becomes simpler and faster while still producing particles that meet the required size specifications for lung perfusion imaging.
Solution Approach 2:
The invention divides the aggregation process into controlled stages with specific pH adjustments and temperature controls. This segmented approach allows precise control over particle formation without requiring complex purification steps, reducing both process time and complexity.
2Manufacturing precision
If conventional processes are used to prepare macroaggregated albumin particles, then the formulation can be produced, but there are variations in particle size distribution and density
Solution Approach 1:
The invention controls particle size and density by precisely adjusting parameters such as pH (lowering to 2-5 during aggregation), temperature (heating to 60-80°C), and stirring speed (200-500 rpm). These controlled parameter changes ensure consistent particle formation with minimal variation in size distribution and density across different batches.
Solution Approach 2:
The process incorporates monitoring and control mechanisms to maintain consistent particle characteristics. By controlling the aggregation conditions with feedback on pH, temperature, and mixing parameters, the invention achieves reliable reproducibility of particle size and density across multiple production lots.
3Manufacturing precision
If ultrafiltration and size screening are performed, then particle quality can be improved, but the process becomes more complex and time-consuming
Solution Approach 1:
The invention extracts and eliminates the ultrafiltration and size screening steps from the conventional process. By directly controlling the aggregation conditions to produce particles of appropriate size, the invention achieves particle quality control without requiring complex separation and purification equipment or operations.
Solution Approach 2:
The invention performs preliminary control of particle formation conditions during the aggregation step itself. By pre-establishing the correct pH, temperature, and mixing conditions before particle formation, the process produces particles of the desired size range without needing subsequent purification or size-based separation steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high lot-to-lot uniformity in particle size distribution and density, improving the quality, accuracy, and reproducibility of radiolabeled macroaggregated albumin products, making them suitable for diagnostic and therapeutic applications.
Implementation Method 1
A robust, simple, and time-saving process for preparing macroaggregated albumin particles using an automated reactor with controlled pH, stirring speed, and heating/cooling rates
Implementation Method 2
A robust, simple, and time-saving process for preparing macroaggregated albumin particles using an automated reactor with controlled pH, stirring speed, and heating/cooling rates
Data Source
AI summary
The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.